Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Neuronetics, Inc. is a publicly traded medical device company that develops, manufactures, and commercializes non-invasive neuromodulation therapies for psychiatric disorders. The company operates primarily within the medical device and mental health treatment industries, with a focus on office-based therapies for clinicians treating depression and related conditions. Its core offering is NeuroStar TMS Therapy, a transcranial magnetic stimulation (TMS) system used to treat major depressive disorder (MDD) and other neuropsychiatric indications.
The company’s primary revenue driver is the sale and leasing of NeuroStar TMS Therapy systems, along with associated service contracts and treatment coils. Neuronetics serves psychiatrists, behavioral health clinics, hospitals, and integrated healthcare systems, positioning itself as a pure-play TMS company with a large installed base and extensive clinical evidence supporting its technology. Founded in 2003, Neuronetics has evolved from a development-stage medical device firm into a commercial-stage company, completing its initial public offering in 2018 and expanding indications and market penetration over time.
Business Operations
Neuronetics operates as a single-reportable-segment company focused on the commercialization of NeuroStar TMS Therapy, generating revenue through system sales, recurring treatment coil usage, and service and maintenance agreements. The company controls proprietary TMS technology, software, and treatment protocols, and supports customers through training, clinical education, and practice development services.
Operations are primarily domestic, with the majority of revenue generated in the United States. International activity is conducted largely through distributor relationships rather than direct sales infrastructure. Based on available public disclosures, Neuronetics does not report material joint ventures and operates without separately disclosed operating subsidiaries; data inconclusive based on available public sources regarding any non-material or inactive entities.
Strategic Position & Investments
Neuronetics’ strategic direction centers on expanding adoption of NeuroStar TMS Therapy through broader clinical indications, increased awareness among providers and patients, and deeper penetration of existing accounts. Growth initiatives include pursuing additional regulatory clearances, enhancing product usability, and leveraging real-world clinical data to support reimbursement and physician adoption.
The company has invested in iterative improvements to its TMS platform rather than large-scale acquisitions, and no transformative acquisitions have been publicly disclosed in recent filings. Neuronetics is positioned within the emerging neuromodulation and interventional psychiatry space, emphasizing evidence-based, non-pharmacologic treatments as alternatives or adjuncts to antidepressant medications.
Geographic Footprint
Neuronetics is headquartered in Malvern, Pennsylvania, and its primary commercial and operational focus is the United States. The company maintains a nationwide sales and support organization serving psychiatric and behavioral health providers across major metropolitan and regional markets.
Internationally, Neuronetics has a presence in Europe, Asia-Pacific, and select other regions primarily through third-party distributors. While international revenue represents a smaller portion of overall sales compared to the U.S., these markets provide incremental growth opportunities and broader global exposure to the NeuroStar TMS Therapy platform.
Leadership & Governance
Neuronetics is led by an executive team with experience in medical devices, healthcare commercialization, and public company management. The leadership team emphasizes disciplined growth, clinical evidence generation, and expanding access to non-invasive mental health treatments.
Key executives include:
- Keith J. Sullivan – President and Chief Executive Officer
- Stephen J. Furlong – Executive Vice President and Chief Financial Officer
Information regarding additional executive leadership roles and founders is limited or inconsistently disclosed across public sources; data inconclusive based on available public sources.